Elsevier Announces 2012 Journal Impact Factor Highlights

           Elsevier Announces 2012 Journal Impact Factor Highlights

  PR Newswire

  AMSTERDAM, July 15, 2013

AMSTERDAM, July 15, 2013 /PRNewswire/ --

Elsevier , a world-leading provider of scientific, technical and medical
information products and services, today announced the highlights of its
journal Impact Factor performance in 2012. According to the 2012 Journal
Citation Reports ^® (JCR) published by Thomson Reuters, Elsevier saw 53% of
its journal Impact Factors increase from 2011 to 2012. Furthermore, 17% of
Elsevier journals are in the top 10% of their subject category, well ahead of
its major commercial competitors.

Elsevier journals top the rankings in 59 subject categories, up from 57 in
2011. Of Elsevier's 1,600 journals in the JCR, 44% are in the top 25% of their
subject category. In 2012, 15 Elsevier journals have risen to the top of their
subject category, including Cell, reclaiming the top position in "Biochemistry
& Molecular Biology".

"Another year of positive results reinforces my view that we're on the right
track as a publisher, but most of the credit should go to the world-class
authors, editors and reviewers", said Philippe Terheggen, Managing Director
Journals at Elsevier. "When we look at these scores, it's important to keep in
mind that while the Impact Factor is an important measure for overall journal
influence, it is not to be used for evaluation of individual researchers or
articles. We're increasingly looking at additional metrics, including so
called Altmetrics, as a measure of influence of journals and authors.
Meanwhile, we will continue to invest in enhancing the quality of our content,
for example by increased support of peer review, by enriching the online
article, and through linking articles to research data sets in external
repositories. That's the journey we're on."

Flagship titles and society journals

All of The Lancet journals' Impact Factors increased. The Lancet rose from
38.278 to 39.060, The Lancet Oncology saw an increase from 22.589 to 25.117
moving up its subject category ranking from 4 ^th to 3 ^rd position. The
Lancet Neurology increased to 23.917, from 23.462, and The Lancet Infectious
Diseases went up from 17.391 to 19.966, both journals maintaining the top
rankings in their respective categories.

The journals of Cell Press , an imprint of Elsevier, mostly saw quite stable
trends in Impact Factor, with highlights including strong growth from
Molecular Cell - an 8% increase to 15.280 and Trends in Cognitive Sciences ,
which saw a 27% increase in comparison to 2011, to 16.008. Its flagship
journal Cell continues to lead in its field with an impact factor of 31.957,
and is the number one research journal in the Cell Biology and Biochemistry &
Molecular Biology categories.

Of the 420 titles in the JCR that Elsevier publishes on behalf of societies,
261, or 62%, showed a rise in their Impact Factors. Nine of these rank number
one in their subject categories, among which Evolution and Human Behavior,
rising from the 4 ^th position in the category "Social Sciences, Biomedical".
Two society journals reached a number one position for the first time:
European Urology reached the number one position in "Urology & Nephrology, and
Forensic Science International: Genetics ranked highest in the category:
"Medicine, Legal".

The Impact Factor helps evaluate a journal's impact compared to others in the
same field by measuring the frequency with which recent articles in a journal
have been cited in a particular year: the 2012 Impact Factor takes into
account citations in 2012 to papers published in 2010 and 2011.

About Elsevier Elsevier is a world-leading provider of scientific, technical
and medical information products and services. The company works in
partnership with the global science and health communities to publish more
than 2,000 journals, including The Lancet and Cell , and close to 20,000 book
titles, including major reference works from Mosby and Saunders. Elsevier's
online solutions include ScienceDirect , Scopus , Reaxys , ClinicalKey and
Mosby's Suite , which enhance the productivity of science and health
professionals, and the SciVal suite and MEDai's Pinpoint Review , which help
research and health care institutions deliver better outcomes more
cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people
worldwide. The company is part of Reed Elsevier Group plc , a world leading
provider of professional information solutions. The group employs more than
30,000 people, including more than 15,000 in North America. Reed Elsevier
Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed
Elsevier NV. Their shares are traded on the London, Amsterdam and New York
Stock Exchanges using the following ticker symbols: London: REL; Amsterdam:
REN; New York: RUK and ENL.

Media contact Tom Reller Vice President, Global Corporate Relations, Elsevier
+1-215-239-3508 t.reller@elsevier.com